Research and Markets(http://www.researchandmarkets.com/research/8a4ac9/acute_ischemic_str) has announced the addition of GlobalData's new report "Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015" to their offering.
Executive Summary:
"Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Acute Ischemic Stroke (AIS) market. The report identifies the key trends shaping and driving the global AIS market. The report also provides insight on the prevalent competitive landscape and the emerging players. Most importantly, the report provides valuable insight on the pipeline products within the global AIS sector.
The Acute Ischemic Stroke Therapeutics Market is Forecast to Show Low Growth till 2015
The authors estimated the global Acute Ischemic Stroke (AIS) market to be valued at $2.9 billion in 2008. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.4% for the next seven years to reach $3.6 billion by 2015. This is primarily attributed to a weak pipeline landscape. Due to the fact that the weak pipeline, the delay in seeking treatment within the three hour therapeutic window, and the clinical trial failure rate continue to pose significant challenges for prospective market entrants, the market landscape in the future is expected to remain static. The ageing population will be a key driver of this market.
A Weak Market with Only One Approved Product for Treating the Acute Phase of the Disease
The authors analyzed the current market landscape and found it to be weak. There is only one approved product and an older generic, aspirin, serving the entire acute phase of the AIS market. Recombinant tissue Plasminogen Activator (rt-PA) treats the acute phase of ischemic stroke and occupies the major market share for the acute phase. However, generics also occupy a considerable market share as the majority of the patient pool is ineligible to receive this treatment. The competitive landscape of the acute phase of the ischemic stroke market is populated by a single product and by some generics for maintenance. The weak point in this landscape is that the only marketed product available has low efficacy and safety. Patient satisfaction remains low and physician satisfaction, in terms of rt-PA, is high only within the three-hour therapeutic window. New entrants into the market will be forced to match or exceed both the efficacy and safety profile of the current marketed product.
A Lucrative Market with High Unmet Need
The report finds that the global AIS market is a highly lucrative market with high unmet needs. The fact that the product currently on the market does not serve the unmet need of a larger therapeutic window, better efficacy and safety, and being suitable for a wider patient pool, results in the market continuing to present opportunities for stronger pipeline candidates. This historically static market offers huge potential for any drug maker whose drug can meet the unmet needs of the market. At the same time, this market is continuously haunted by high clinical trial failure making it a market with high commercial risk. The clinical trial failure is mainly due to poor clinical trial design, certain methodological defects, and high animal model unpredictability. This is a market with huge potential for opportunity for which technologically innovative products will be required for value capture. However, if a company wants to capture this unmet need, it will need to overcome prevailing product weaknesses and major adverse effects such as Intracranial Hemorrhage (ICH). Currently, these are the biggest challenges preventing most pipeline products from capturing the unmet need of this market
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
Scope
The scope of the report includes: